产品说明书
Methyclothiazide
 |
同义名 : | NSC 110431 |
| CAS号 : | 135-07-9 | |
| 货号 : | A407281 | |
| 分子式 : | C9H11Cl2N3O4S2 | |
| 纯度 : | 98% | |
| 分子量 : | 360.237 | |
| MDL号 : | MFCD00242610 | |
| 存储条件： |
粉末 Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 75 mg/mL(208.2 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Methyclothiazide is a substituted benzothiadiazide, used to treat high blood pressure and fluid retention caused by various conditions including heart disease. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00208429 | Rheumatoid Arthritis ... 展开 >> Osteoarthritis Post-traumatic Arthritis Collagen Disorders Avascular Necrosis Traumatic Femoral Fractures Nonunion of Femoral Fractures Congenital Hip Dysplasia Slipped Capital Femoral Epiphysis 收起 << | Phase 4 | Withdrawn(Site Principal Inves... 展开 >>tigator became seriously ill, so study abandoned before the start of recruitment) 收起 << | July 1, 2019 | - |
| NCT01121146 | Osteoarthritis ... 展开 >> Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases 收起 << | Not Applicable | Completed | - | United States, Virginia ... 展开 >> Anderson Orthopaedic Research Institute Alexandria, Virginia, United States, 22306 收起 << |
| NCT00208442 | Osteoarthritis ... 展开 >> Post-traumatic Arthritis Collagen Disorders Avascular Necrosis Traumatic Femoral Fractures Nonunion of Femoral Fractures Congenital Hip Dysplasia Slipped Capital Femoral Epiphysis 收起 << | Phase 4 | Completed | - | New Zealand ... 展开 >> University Otago, Wellington Medical School of Medicine Wellington, New Zealand 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.78mL 0.56mL 0.28mL |
13.88mL 2.78mL 1.39mL |
27.76mL 5.55mL 2.78mL |
| 参考文献 |
|---|